Eris Lifesciences Ltd · NSE:ERIS
Eris Lifesciences — Q1 FY22 Earnings Presentation
17 slides from Eris Lifesciences's earnings presentation, Jul 29, 2021
Slide 1: Intimation letter to BSE and NSE: Investor Presentation
Date: 29th July, 2021 To To BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza Dalal Street Bandra Kurla Complex Mumbai- 400001 Bandra (E) Mumbai-400051 Security Code: 540596 Symbol: ERIS SUBJECT: INVESTOR PRESENTATION Dear Sir/Madam, Pursuant to the requir
Slide 2: Q1 FY 22 Investor Presentation
Q1 FY 22 INVESTOR PRESENTATION 29th July 2021 1
Slide 3: Q1 FY 22 – Financial Highlights
Q1 FY 22 – FINANCIAL HIGHLIGHTS INR mn INR mn INR mn 3,493 1,265 1,067 19.1% 21.6% 19.8% Op Revenue yoy growth EBITDA yoy growth PAT yoy growth • Consolidated Operating revenue grew by 19.1% yoy in Q1 FY 22 • Branded formulations products sales grew by 19.6% yoy in Q1 FY 22 • Standalone gross margin
Slide 4: Top-10 Companies by Growth (MAT Jun 21) - IPM excluding Covid drugs
TOP-10 COMPANIES BY GROWTH (MAT JUN 21) - IPM EXCLUDING COVID DRUGS* 24.9% 21.1% 19.8% 18.9% 14.4% 13.9% 13.4% 13.3% 12.8% 12.5% 10.2% IPM excl. Covid EMC URE* CADILA ARISTO IPCA CIPLA ALKEM* ERIS LS MACLEODS PFIZER* MICRO % Acute Therapy 45% 36% 36% 68% 66% 42% 58% 9% 45% 56% 44% contribution1 IPM
Slide 5: Q1 FY 22 – Business Highlights – Eris Outperforms in Core Therapies
Q1 FY 22 – BUSINESS HIGHLIGHTS – ERIS OUTPERFORMS IN CORE THERAPIES Eris grew at 30.3% yoy in Q1 FY22 vs. IPM (excl. Covid molecules) which grew at 34.1% yoy in Q1 FY22 • Eris substantially outperformed the IPM in its Top-3 therapeutic segments accounting for 88% of Eris’ Q1 FY22 revenue Cardio-Meta
Slide 6: Q1 FY 22 – New Product Launches
Q1 FY 22 – NEW PRODUCT LAUNCHES New Product Launches in Q1 FY 22 : Our newly launched brand in Remogliflozin+Vildagliptin combination : Our new offering in Vitamin D+Methylcobalamin market : A lower dose version of our previous offering Zac D Update on Latest Generation Diabetes products • Among the
Slide 7: Q1 FY 22 - Prescription Ranking Among Doctor Specialties
Q1 FY 22 - PRESCRIPTION RANKING AMONG DOCTOR SPECIALTIES Eris Prescription Ranking* among Doctor Specialties 4 3 3 CARDIOLOGISTS DIABETOLOGISTS NEUROLOGISTS 4 CONSULTING 6 GASTROENTEROLOGISTS PHYSICIANS Source: SMSRC MAT Jun 2021 * Rank in Represented Market 6
Slide 8: Power Brands Continue to Have Leading Presence in Core Therapies
Q1 FY 22 - POWER BRANDS CONTINUE TO HAVE LEADING PRESENCE IN CORE THERAPIES Therapy wide presence in Oral Diabetes Care with power brands holding high ranks in Newer-generation fast-growing molecules Sulfonylurea rank 5 in the ≈4,600 cr Glimepiride and combinations market Glimisave MV rank 2 in Glim
Slide 9: Power Brands Continue to Have Leading Presence in Core Therapies
Q1 FY 22 - POWER BRANDS CONTINUE TO HAVE LEADING PRESENCE IN CORE THERAPIES High rank in Anti-Hypertensives: the fastest growing and largest segment of Cardiac Care rank 5 in the ≈3,500 cr Telmisartan and combinations market Eritel CH rank 4 in Telmisartan + Chlorthalidone market Eritel LN rank 2 in
Slide 10: Key Growth Drivers (1/2)
KEY GROWTH DRIVERS (1/2) Expansion of power-brands’ • Our business model of building strong and sustainable brands has enabled us to maintain 1 our growth trajectory during the pandemic periods (Wave 1 as well as Wave 2) when MR- franchise Doctor interactions were severely constrained • There has be
Slide 11: Key Growth Drivers (2/2)
KEY GROWTH DRIVERS (2/2) Expansion of physician • We plan to significantly expand our coverage of Specialists and Consulting Physicians in 3 coverage the next 5 years Therapeutic Diversification • We are investing in diversification opportunities in high-growth areas like neurology, 4 women’s health
Slide 12: Long Term Manufacturing Strategy – Capacity Expansion
LONG TERM MANUFACTURING STRATEGY – CAPACITY EXPANSION • Our Guwahati facility was commercialized in FY15 and accounted for 81% of our products sold in Q1 FY22 • The capacity utilization of the Rx tablets block at Guwahati has presently reached ~ 60% and we expect it to achieve ~ 80% capacity utiliza
Slide 13: Q1 FY 22 - Standalone Income Statement
Q1 FY 22 - STANDALONE INCOME STATEMENT Standalone Q1 FY 22 INR Millions Q1 FY22 Q1 FY21 YOY Gr % Sale of Products 3,003 2,561 17.3% • Operating Revenue grew by 17.1% yoy in Q1 FY22 Other Operating Income 60 54 11.0% Revenue from Operations 3,063 2,615 17.1% • Standalone gross margin of 84.8% in Q1 F
Slide 14: Q1 FY 22 - Consolidated Income Statement
Q1 FY 22 - CONSOLIDATED INCOME STATEMENT Consolidated Q1 FY 22 INR Millions Q1 FY22 Q1 FY21 YOY Gr % Branded Formulation Sales Sale of Products 3,437 2,881 19.3% Q1 FY 22 INR Millions Q1 FY 22 Q1 FY 21 Other Operating Income 56 52 8.8% yoy GR Revenue from Operations 3,493 2,932 19.1% Sale of Product
Slide 15: Shareholder Profile
SHAREHOLDER PROFILE Shareholding of Promoters and Top 15 Institutional Investors Others, As on As on As on FPIs, 0.54% Name of Shareholder 30-Jun-21 31-Mar-21 31-Dec-20 13.49% 696* 605* 580* Promoters 52.69% 54.13% 54.23% 1 ChrysCapital (Emerald Investment Limited) 5.51% 5.51% 5.51% DIIs, 2 UTI Mutu
Slide 16: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward- looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and the underlying assumptions
Slide 17: Thank You
THANK YOU KRUTI RAVAL INVESTOR RELATIONS kruti@erislifesciences.com 16